Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3680 (Rezvilutamide) plus ADT vs bicalutamide plus ADT in metastatic hormone‑sensitive prostate cancer with high tumor load
2024-515194-10-00Phase 3Authorised
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of rezvilutamide in prostate adenocarcinoma (2 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Radiographic progression-free survival (rPFS) and Overall survival (OS). Planned start Nov 2024; status: authorised.
02
Drugs
rezvilutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2024-515194-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515194-10-00.